stockrowLivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.88%
- EPS
- +27.4%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) Return on assets
LivaNova PLC's return on assets over the twelve months to 30 September 2026 was 7.44%, up 16.9 percentage points from fiscal 2025 (−9.49%). Over the past ten years it has ranged from −14.5% (fiscal 2020) to 19.0% (fiscal 2015); the current reading is higher than 17% of that period. That is above the Medical Devices industry median of −17.3% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −9.49% | (12.05) |
| FY2024 | 2.56% | 1.82 |
| FY2023 | 0.74% | 4.58 |
| FY2022 | −3.84% | 2.06 |
| FY2021 | −5.90% | 8.60 |
| FY2020 | −14.5% | (8.15) |
| FY2019 | −6.35% | 1.15 |
| FY2018 | −7.50% | (6.46) |
| FY2017 | −1.04% | 1.52 |
| FY2016 | −2.56% | (2.56) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| BIO Bio-Rad Laboratories, Inc. compare | 9.99% |
| LIVN LivaNova PLC | 7.44% |
| HAE Haemonetics Corporation compare | 4.28% |
| ITGR Integer Holdings Corporation compare | 3.05% |
| NEOG Neogen Corporation compare | −1.68% |
| BRKR Bruker Corporation compare | −2.73% |
| IRTC iRhythm Holdings, Inc. compare | −3.70% |
| TXG 10x Genomics compare | −7.47% |
| AXGN AxoGen, Inc. compare | −8.33% |
| Medical Devices industry median | −17.3% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on LIVN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement